Literature DB >> 26157324

Comparison of the clinical characteristics and survival between Uyghur patients with hepatitis virus-related and non-B, non-C hepatocellular carcinoma in Xinjiang, China.

Lei Xiao1, Rui-Li Zhang1, Hua Zhang1, Aisiker Tulahong1, Yue-Fen Zhang1, Hao Wen1, Yong-Xing Bao1.   

Abstract

OBJECTIVE: To compare the clinical characteristics and prognosis between hepatitis virus-related hepatocellular carcinoma (viral HCC) and non-B, non-C HCC (NBC-HCC) among Uyghur patients in Xinjiang province, China.
METHODS: Between 01/01/2000 and 31/12/2012, 319 Uyghur HCC patients were treated at the Cancer Centre of The First Affiliated Hospital of Xinjiang Medical University. The data for the patients were obtained from a retrospective review of the patients' medical records. A total of 18 patients were excluded from the study because of incomplete information. The patients were classified into two groups: viral HCC and NBC-HCC. The clinical characteristics and prognostic factors were statistically analysed.
RESULTS: For all 301 patients, gender (P=0.000), area of residence (P=0.002), diabetes mellitus (P=0.009), BMI (P=0.000), cirrhosis (P=0.000), tumour stage (P=0.004), Child-Pugh class (P=0.000), the TBIL level (P=0.000), and the alpha-fetoprotein (AFP) level (P=0.000) were significantly different between the NBC-HCC and viral HCC groups. The NBC-HCC patients tended to be diagnosed at advanced stages; however, the NBC-HCC patients exhibited lower Child-Pugh scores than the viral HCC patients. In all patients examined, the 0.5-, 1-, 3- and 5-year overall survival (OS) rates were 35.6%, 20.3%, 12.6% and 4.5%, respectively. No significant difference in OS was observed between the two groups (P=0.124). Cox multivariate analysis revealed that age (RR =1.539, P=0.001), TNM stage (RR =12.708, P=0.000), portal vein tumour thrombus (PVTT) (RR =2.003, P=0.000), Child-Pugh class (RR =1.715, P=0.000), and TACE + radiotherapy/RFA (RR =0.567, P=0.000) were significant independent prognostic factors for HCC patients.
CONCLUSIONS: The clinical characteristics differ between Uyghur patients with NBC-HCC and viral HCC. HCC in the Xinjiang region displays specific regional characteristics. Age, TNM stage, PVTT, Child-Pugh class and TACE + radiotherapy/RFA are significant risk factors that influence patient survival.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); Uyghur people; clinical characteristics; hepatitis virus-related HCC (viral HCC); non-B, non-C HCC (NBC-HCC)

Year:  2015        PMID: 26157324      PMCID: PMC4490201          DOI: 10.3978/j.issn.1000-9604.2015.01.04

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  19 in total

1.  Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution's experience with 398 consecutive patients.

Authors:  Zheng-Gui Du; Yong-Gang Wei; Ke-Fei Chen; Bo Li
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2014-04

Review 2.  New aspects of diagnosis and therapy of hepatocellular carcinoma.

Authors:  J Bruix; A J Hessheimer; A Forner; L Boix; R Vilana; J M Llovet
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

3.  Prevalence of the metabolic syndrome and overweight among adults in China.

Authors:  Dongfeng Gu; Kristi Reynolds; Xigui Wu; Jing Chen; Xiufang Duan; Robert F Reynolds; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

4.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford; Wayne H Giles; William H Dietz
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

5.  Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients.

Authors:  Takumi Akiyama; Toshihiko Mizuta; Seiji Kawazoe; Yuichiro Eguchi; Yasunori Kawaguchi; Hirokazu Takahashi; Iwata Ozaki; Kazuma Fujimoto
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

6.  Clinical characteristics of non-B non-C hepatocellular carcinoma: a single-center retrospective study.

Authors:  Soo Ki Kim; Hiroyuki Marusawa; Yuji Eso; Hiroki Nishikawa; Yoshihide Ueda; Ryuichi Kita; Toru Kimura; Tsutomu Chiba; Yukio Osaki; Masatoshi Kudo
Journal:  Digestion       Date:  2011-12-02       Impact factor: 3.216

7.  Family history of liver cancer and hepatocellular carcinoma.

Authors:  Federica Turati; Valeria Edefonti; Renato Talamini; Monica Ferraroni; Matteo Malvezzi; Francesca Bravi; Silvia Franceschi; Maurizio Montella; Jerry Polesel; Antonella Zucchetto; Carlo La Vecchia; Eva Negri; Adriano Decarli
Journal:  Hepatology       Date:  2012-03-21       Impact factor: 17.425

8.  Evolution of prognostic factors in hepatocellular carcinoma in Japan.

Authors:  K Nouso; Y Kobayashi; S Nakamura; S Kobayashi; J Toshimori; K Kuwaki; H Hagihara; H Onishi; Y Miyake; F Ikeda; H Shiraha; A Takaki; Y Iwasaki; H Kobashi; K Yamamoto
Journal:  Aliment Pharmacol Ther       Date:  2009-10-22       Impact factor: 8.171

Review 9.  Strategies for the management of hepatocellular carcinoma.

Authors:  Myron Schwartz; Sasan Roayaie; Manousos Konstadoulakis
Journal:  Nat Clin Pract Oncol       Date:  2007-07

10.  Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma.

Authors:  Hiroki Nishikawa; Akira Arimoto; Tomoko Wakasa; Ryuichi Kita; Toru Kimura; Yukio Osaki
Journal:  J Cancer       Date:  2013-07-18       Impact factor: 4.207

View more
  1 in total

Review 1.  The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis.

Authors:  Soheil Hassanipour; Mouhebat Vali; Saber Gaffari-Fam; Hossein-Ali Nikbakht; Elham Abdzadeh; Farahnaz Joukar; Akram Pourshams; Afshin Shafaghi; Mahdi Malakoutikhah; Morteza Arab-Zozani; Hamid Salehiniya; Fariborz Mansour-Ghanaei
Journal:  EXCLI J       Date:  2020-01-13       Impact factor: 4.068

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.